Aduro BioTech

Type: Company
Name: Aduro BioTech
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Where are we now with Gene Therapy?

Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy ... [Published Terrapinn - Apr 11 2014]
First reported Apr 09 2014 - Updated Apr 10 2014 - 1 reports

Vaccine Market By Technology & Types, Various Classes & Indications - Global Forecasts To 2022

DUBLINResearch and Markets ( http://www.researchandmarkets.com/research/fkn6g5/vaccine_market_by) has announced the addition of the report to their offering.(Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global vaccine technology market ... [Published TheStreet.com - Apr 09 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Malignant Mesothelioma Global Clinical Trials Review, H1, 2014

Reportstack has announced a new market research publication on   which provides elemental information and data relating to the clinical trials on Malignant Mesothelioma. It includes an overview of the trial numbers and their recruitment status as per ... [Published PitchEngine - Apr 01 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

BDP Week: Takeways from Day One

Today kicked off Biopharmaceutical Development and Production Week in San Diego. Here are just a few highlights from today's sessions:Peter H. Calcott, President, of Calcott Consulting LLC shared that the key content found in any quality agreement ... [Published Future of BioPharma - Mar 25 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

Vaccine Technology Market worth $84.44 Billion By 2022

Browse 22 market data tables and 53 figures spread through 195 pages and in-depth TOC Vaccine Market - By Technology & Types, Trend Analysis By Various Classes – Live / Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic ... [Published PitchEngine - Mar 14 2014]
First reported Feb 10 2014 - Updated Feb 10 2014 - 1 reports

BioNews – 02/10/14

Top News HeadlineCompanyType U.K.'s Medical Research Council commits $52M to medical record bioinformatics Medical Research CouncilBioInformatics The FDA is making adverse event and recall data available to app developers FDAApps Report: Boston Scientific, ... [Published eClinical Trends - Feb 10 2014]
First reported Feb 10 2014 - Updated Feb 10 2014 - 12 reports

Aduro BioTech Announces Initiation of Phase 2b ECLIPSE Trial to Evaluate Treatment of Patients with Pancreatic Cancer with the Company’s Innovative Immunotherapies

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. today announced the initiation of a Phase 2b clinical trial of the company’s immunotherapies GVAX Pancreas and CRS-207. The first patient has been treated in the randomized, controlled, multicenter ... [Published EON Transportation - Feb 10 2014]
First reported Jan 30 2014 - Updated Jan 30 2014 - 12 reports

Aduro Announces Presentations at the Upcoming BIO CEO and Investor Conference and Leerink Global Healthcare

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical stage biotechnology company, today announced that the company’s chairman and chief executive officer, Stephen T. Isaacs, will present a company overview at the following upcoming c ... [Published Yahoo! Finance - Jan 30 2014]
First reported Dec 11 2013 - Updated Dec 11 2013 - 1 reports

Vaccine Technology Market (Live / Attenuated, Subunit, Toxoid, Conjugate) Worth $84.44 Billion By 2022 - New Report by MarketsandMarkets

Vaccine Technology Market report categorizes the global vaccine market into technology class, types, end users, disease indication, and geography - The "Vaccine Market - By Technology & Types, Trend Analysis By Various Classes – Live / Attenuated, Subunit, ... [Published PRWeb - Dec 11 2013]
Entities: Vaccine, Toxoid, Market
First reported Oct 30 2013 - Updated Oct 30 2013 - 1 reports

Vaccine Technology Market (Live / Attenuated, Subunit, Toxoid,...

Vaccine Technology Market report categorizes the global vaccine market into technology class, types, end users, disease indication, and geography.MarketsandMarkets The "Vaccine Market - By Technology & Types, Trend Analysis By Various Classes – Live / ... [Published PRWeb - Oct 30 2013]
Entities: Vaccine, Toxoid, Market
First reported Oct 22 2013 - Updated Oct 22 2013 - 1 reports

FDA grants orphan drug designation to Aduro's CRS207 for treatment of pancreatic cancer

Home » Syndicated Content » FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancerAduro BioTech, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan ... [Published BioPortfolio - Oct 22 2013]

Quotes

2022 " analyzes and studies the major market drivers, restraints, and"
...Technology Market report categorizes the global vaccine market into technology class, types, end users, disease indication, and geography - The "Vaccine Market - By Technology & Types, Trend Analysis By Various Classes – Live / Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic Vaccines And By Indications – Infectious Diseases, Cancer, Allergy, Diabetes, Cardiovascular Disease With Market Landscape Analysis - Global Forecasts To 2022 " analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and the Rest of the World
More From BioPortfolio on "FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer"

More Content

All (34) | News (9) | Reports (0) | Blogs (25) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Where are we now with Gene Therapy? [Published Terrapinn - Apr 11 2014]
Vaccine Market By Technology & Types, Various C... [Published TheStreet.com - Apr 09 2014]
Malignant Mesothelioma Global Clinical Trials R... [Published PitchEngine - Apr 01 2014]
BDP Week: Takeways from Day One [Published Future of BioPharma - Mar 25 2014]
Vaccine Technology Market worth $84.44 Billion ... [Published PitchEngine - Mar 14 2014]
BioNews – 02/10/14 [Published eClinical Trends - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Transportation - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Environment - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Manufacturing - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Retail - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Consumer - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Communications - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Energy - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Business - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON: Enhanced Online News - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Science - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published Business Wire Science: Science News - Feb 10 2014]
Aduro BioTech Announces Initiation of Phase 2b ... [Published Business Wire Health News - Feb 10 2014]
Aduro Announces Presentations at the Upcoming B... [Published Yahoo! Finance - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published EON Transportation - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published EON Environment - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published EON Retail - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published EON Communications - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published EON Manufacturing - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published EON Energy - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published EON Consumer - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published EON: Enhanced Online News - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published EON Science - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published Business Wire Health News - Jan 30 2014]
Aduro Announces Presentations at the Upcoming B... [Published Business Wire Science: Science News - Jan 30 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BDP Week: Takeways from Day One [Published Future of BioPharma - Mar 25 2014]
Today kicked off Biopharmaceutical Development and Production Week in San Diego. Here are just a few highlights from today's sessions:Peter H. Calcott, President, of Calcott Consulting LLC shared that the key content found in any quality agreement ...
BioNews – 02/10/14 [Published eClinical Trends - Feb 10 2014]
Top News HeadlineCompanyType U.K.'s Medical Research Council commits $52M to medical record bioinformatics Medical Research CouncilBioInformatics The FDA is making adverse event and recall data available to app developers FDAApps Report: Boston Scientific, ...
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Transportation - Feb 10 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. today announced the initiation of a Phase 2b clinical trial of the company’s immunotherapies GVAX Pancreas and CRS-207. The first patient has been treated in the randomized, controlled, multicenter ...
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Environment - Feb 10 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. today announced the initiation of a Phase 2b clinical trial of the company’s immunotherapies GVAX Pancreas and CRS-207. The first patient has been treated in the randomized, controlled, multicenter ...
Aduro BioTech Announces Initiation of Phase 2b ... [Published EON Manufacturing - Feb 10 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. today announced the initiation of a Phase 2b clinical trial of the company’s immunotherapies GVAX Pancreas and CRS-207. The first patient has been treated in the randomized, controlled, multicenter ...
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.